Slide 1: Corporate Presentation March 2026
Corporate Presentation March 2026 For personal use only
Slide 2: Business Snapshot
Business Snapshot Compumedics (ASX: CMP) is a leading global medical technology company focused on sleep, neurological disorders and ultrasonic brain blood flow monitoring. For personal use only Technology Australia based, Generated $31m of developer/leader in with wholly owned Long track record, Gl
Slide 3: Executive Summary
Executive Summary Record H1 performance with accelerating recurring revenue and improving earnings quality For personal use only Record Sales Orders Record Sales Revenue EBITDA $34.9M $31.0M $3.1M Up +6% on H1 FY25 Up +32% on H1 FY25 Up +343% on H1 FY25 Up +20% on H1 FY24 Up +17% on H1 FY24 Platform
Slide 4: Board and Management
Board and Management Strengthened leadership and governance to support the next phase of growth For personal use only Strengthened Board Renewal Execution Systems and Performance Executive Team Capability Controls Focus 1. Targeted hires 2. Chris Barys was 3. Broader operating 4. Continued 5. Leader
Slide 5: H1 FY26 Financial Performance
H1 FY26 Financial Performance For personal use only
Slide 6: H1 FY26 Financial Results
H1 FY26 Financial Results Compumedics is building earnings momentum through revenue growth, recurring revenue expansion & cost discipline Sales Orders ($M) Sales Revenue ($M) USA Revenue ($M) For personal use only Record sales orders H1 FY26 up +6% YoY Record sales revenue H1 FY26 up +32% YoY USA re
Slide 7: H1 FY26 Financial Performance
H1 FY26 Financial Performance Compumedics produced YoY growth across all major financial metrics in H1 FY26 Financial Performance For personal use only FY25 Highlights: $M H1 FY24A H1 FY25A H1 FY26A FY26F • Record Sales Orders: $34.9M, up +6% YoY • Record Revenue: $31.0M, up +32% YoY Sales Orders 29
Slide 8: Business Model and Revenue Diversification
Business Model and Revenue Diversification Diversified revenue base across multiple geographies and segments Geography Segment For personal use only USA: Sleep & SaaS: • High-end PSG systems + rapidly scaling Somfit SaaS platform • Core growth driver with sleep and neuro acceleration • Clinical-grad
Slide 9: Segment Performance & Outlook
Segment Performance & Outlook For personal use only
Slide 10: Segment Overview & Performance
Segment Overview & Performance Compumedics’ technology is focused on the fast growing, high value sleep diagnostics market and the associated fields of neuro-diagnostics and brain research For personal use only Sleep & SaaS ($M) H1 FY25 H1 FY26 YoY% Neuro Monitoring & Research ($M) H1 FY25 H1 FY26 Y
Slide 11: Sleep & SaaS
Sleep & SaaS SaaS-Driven Sleep Diagnostics Leadership: High-Growth Momentum, Scalable Model, Global Traction % H1 FY26 Example Products / Solutions Business Growth & Strategic Highlights For personal use only Sales Orders Market Positioning & Opportunity (Not Exhaustive) • Strong growth from install
Slide 12: Neuro Monitoring & Research
Neuro Monitoring & Research Pioneering Neurotech with Scalable MEG Growth and Global Clinical Traction For personal use only % H1 FY26 Example Products / Solutions Business Sales Orders Growth & Strategic Highlights Market Positioning & Opportunity (Not Exhaustive) • Wireless Okti EEG adoption expan
Slide 13: Blood flow & TCD (DWL)
Blood flow & TCD (DWL) AI-Driven TCD Innovation: Commercial Momentum in a $12B Stroke Market % H1 FY26 Example Products / Solutions For personal use only Business Sales Orders Growth & Strategic Highlights Market Positioning & Opportunity (Not Exhaustive) Bloodflow & TCD (DWL) • H1 FY26 revenue of $
Slide 14: Service & Supplies (Recurring)
Service & Supplies (Recurring) High-Margin Recurring Revenue Powering Platform Stickiness and Scale % H1 FY26 Example Products / Solutions For personal use only Business Sales Orders Growth & Strategic Highlights Market Positioning & Opportunity (Not Exhaustive) Service & Okti® Child Disposable Supp
Slide 15: Investment Case
For personal use only Investment Case
Slide 16: Investment Case
Investment Case Positioned for scalable growth and earnings uplift through recurring revenue and U.S. expansion Established global leader in sleep and neurodiagnostics Investment Highlights 1 Long-standing clinical presence with a recognised position across sleep and brain For personal use only heal
Slide 17: Breakout Growth Platforms
Breakout Growth Platforms Somfit ® SaaS OrionMEG® • Somfit ® SaaS – $6.7M (+49%), FDA cleared, • OrionMEG®: ~$13.6B (10% MRI-equivalent adoption) For personal use only • >700k studies, $10M+ U.S. pipeline; Philips Pharmacy Strategic Partnership; Resmed Major Client; Major Deals: Big Pharmaceutical C
Slide 18: Positioned for Transformational Growth & Re-Rating
Positioned for Transformational Growth & Re-Rating Why Invest Now • Compumedics currently trades at ~A$0.32 per share, implying a market capitalisation of approximately $60-$70 million and enterprise value of $70-$80 million. For personal use only • This equates to 1-1,1x FY26 revenue and 8-9x FY26
Slide 19: Growth & Outlook
For personal use only Growth & Outlook
Slide 20: Growth & Outlook
Growth & Outlook Record H1 performance supports FY26 delivery and earnings momentum Growth Opportunities FY26 Target For personal use only • Revenue growth of +37% YoY to $70.0M U.S. market opportunity remains significant, with large underdiagnosed • EBITDA expansion to $9.0M supported by mix and sc
Slide 21: Disclaimer
Disclaimer This presentation has been prepared by Compumedics Limited (CMP). For personal use only While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliabili
Slide 22: Thank You
For personal use only Thank You